IP Library Granted Patent US 9,308,225
Granted Patent B2
US 9,308,225 · App. 14/671,360 · Granted Apr 12, 2016

Compositions and methods for preventing cardiac arrhythmia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,308,225
App. No.
14/671,360
Granted
Apr 12, 2016
Kind
B2
Abstract

Disclosed herein are compositions and methods for treating or preventing cardiac arrhythmia in a subject.

Claims (6)

1. A method of treating post-operative atrial fibrillation in a subject, comprising:

providing an extracellular matrix (ECM) composition comprising acellular ECM from a mammalian tissue source, said tissue source comprising small intestine submucosa, wherein, when said ECM composition is administered to damaged myocardium tissue of said subject, said ECM composition induces myofibroblast proliferation and angiogenesis and, thereby, bioremodeling and regeneration of new myocardium tissue; and

delivering a therapeutically effective amount of said ECM composition directly to post-operative damaged myocardium tissue of said subject, wherein said ECM composition, wherein said ECM composition modulates electrical activity in the heart of said subject, whereby said ECM composition reduces incidence of post-operative atrial fibrillation of said subject.

2. A method of treating post-operative atrial fibrillation in a subject, comprising:

providing an extracellular matrix (ECM) composition comprising acellular ECM from a mammalian tissue source, said tissue source comprising amniotic membrane, wherein, when said ECM composition is administered to damaged myocardium tissue of said subject, said ECM composition induces myofibroblast proliferation and angiogenesis and, thereby, bioremodeling and regeneration of new myocardium tissue; and

delivering a therapeutically effective amount of said ECM composition directly to post-operative damaged myocardium tissue of said subject, wherein said ECM composition, wherein said ECM composition modulates electrical activity in the heart of said subject, whereby said ECM composition reduces incidence of post-operative atrial fibrillation of said subject.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 12, 2025
From: CORMATRIX CARDIOVASCULAR, INC.
To: CORVIVO CARDIOVASCULAR, INC.
Reel/Frame 070482/0001 →
CHANGE OF NAME Recorded Sep 15, 2023
From: AZIYO BIOLOGICS, INC.
To: ELUTIA INC.
Reel/Frame 064923/0361 →
CHANGE OF NAME Recorded Sep 15, 2023
From: AZIYO MED, LLC
To: ELUTIA MED LLC
Reel/Frame 064923/0704 →
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2022
From: AZIYO BIOLOGICS, INC.; AZIYO MED, LLC
To: MIDCAP FUNDING IV TRUST
Reel/Frame 061164/0532 →
RELEASE OF SECURITY INTEREST Recorded Aug 12, 2022
From: AZIYO BIOLOGICS, INC.; AZIYO MED, LLC
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061161/0001 →
RELEASE OF SECURITY INTEREST Recorded Jun 2, 2017
From: MIDCAP FINANCIAL TRUST
To: CORMATRIX CARDIOVASCULAR, INC.
Reel/Frame 042669/0559 →
SECURITY INTEREST Recorded Sep 30, 2015
From: CORMATRIX CARDIOVASCULAR, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 036732/0103 →